ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 274

Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.

Yuji Hosono1, Ran Nakashima1, Kosaku Murakami1, Yoshitaka Imura1, Satoshi Serada2, Minoru Fujimoto3, Hajime Yoshifuji1, Koichiro Ohmura4, Tetsuji Naka5 and Tsuneyo Mimori4, 1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, 3Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, 4Kyoto University Graduate School of Medicine, Kyoto, Japan, 5Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, dermatomyositis, interstitial lung disease, myositis and viruses

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  

Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD), but the pathogenesis is still unclear. We noticed that the sera from many anti-MDA5 antibody positive patients immunoprecipitated the common 110kDa polypeptide. Thus we intended to identify the autoantigen and investigated the clinical significance.

Methods:  

Autoantibodies were screened in 340 patients with various connective tissue diseases (CTDs) and 15 healthy controls (HCs) by immunoprecipitation with [35S]methionine-labeled HeLa cells. Immunoabsorbent column chromatography was used to purify the reactive autoantigen and the polypeptide was analyzed by peptide mass fingerprinting.

Results:  Anti-110 kDa antibody was detected in 25 DM/CADM patients but not in patients with other CTDs or HCs. All patients with anti-110 kDa antibody were also positive for anti-MDA5 antibody, and had interstitial lung disease. The corresponding polypeptide was identified as splicing factor proline/glutamine-rich protein (SPFQ). Anti-SFPQ antibody was detected at diagnosis and newly appeared in some patients during the disease course. The onsets of DM/CADM had seasonal patterns and showed two peaks according to the temporal appearance of anti-SFPQ antibody. 67% (8/12) of disease onset of patients who had anti-SFPQ antibody at diagnosis were between August and October, whereas 69% (9/13) of those who had newly appearing anti-SFPQ antibody during the disease course were between January and March.

Conclusion:  

We identified the anti-110 kDa antibody as DM/CADM specific autoantibody that recognizes SFPQ in patients who also have anti-MDA5 antibody. The onset of DM/CADM with anti-MDA5 antibody had seasonality according to the appearance time of the antibody to SFPQ, which has a role in innate immune responses. These findings may provide new insights into the pathogenesis of DM/CADM with anti-MDA5 antibody.


Disclosure: Y. Hosono, None; R. Nakashima, None; K. Murakami, None; Y. Imura, None; S. Serada, None; M. Fujimoto, None; H. Yoshifuji, None; K. Ohmura, None; T. Naka, None; T. Mimori, None.

To cite this abstract in AMA style:

Hosono Y, Nakashima R, Murakami K, Imura Y, Serada S, Fujimoto M, Yoshifuji H, Ohmura K, Naka T, Mimori T. Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody. [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/splicing-factor-prolineglutamine-rich-is-a-novel-autoantigen-of-dermatomyositis-and-associated-with-anti-melanoma-differentiation-associated-gene-5-antibody/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/splicing-factor-prolineglutamine-rich-is-a-novel-autoantigen-of-dermatomyositis-and-associated-with-anti-melanoma-differentiation-associated-gene-5-antibody/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology